glipizide
Selected indexed studies
- Clinical pharmacokinetics of glipizide: a systematic review. (Expert Opin Drug Metab Toxicol, 2025) [PMID:39267225]
- Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use. (Pharmacotherapy, 1985) [PMID:3923454]
- Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. (Clin Pharm, 1984) [PMID:6435940]
_Worker-drafted node — pending editorial review._
Connections
glipizide is a side effect of
Sources
- Clinical pharmacokinetics of glipizide: a systematic review. (2025) pubmed
- Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use. (1985) pubmed
- Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. (1984) pubmed
- Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. (2000) pubmed
- Glipizide: an oral hypoglycemic drug. (1989) pubmed
- Glipizide: an overview. (1983) pubmed
- Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status. (2024) pubmed
- Glipizide: a review of its pharmacological properties and therapeutic use. (1979) pubmed
- Glipizide ameliorates human poly(Q) mediated neurotoxicity by upregulating insulin signalling in Drosophila disease models. (2023) pubmed
- Glipizide Combined with ANP Suppresses Breast Cancer Growth and Metastasis by Inhibiting Angiogenesis through VEGF/VEGFR2 Signaling. (2022) pubmed